Issue 5, 2015

Synthesis and evaluation of anticancer activity of novel andrographolide derivatives

Abstract

A series of 3,19-O-acetal derivatives of andrographolide (1) have been synthesized by protecting the hydroxyls at C-3 and C-19 through a novel route. All the derivatives were evaluated for in vitro anticancer activity. Among the synthesized derivatives, compounds 3, 3a, 3d, 3e, 7 and 8 showed potential cytotoxicity against human cancer cell lines A549 (lung), HeLa (cervical), ACHN (renal), B-16 (melanoma) and IEC-6 (small intestine). The binding mode conformation was evaluated through docking simulations, while bioavailability/drug-likeness was evaluated through predictive ADME screening studies. All the derivatives were characterized by spectroscopy and the stereochemistry of compounds 3a and 3e was also confirmed by X-ray analysis.

Graphical abstract: Synthesis and evaluation of anticancer activity of novel andrographolide derivatives

Supplementary files

Article information

Article type
Concise Article
Submitted
17 Dec 2014
Accepted
06 Mar 2015
First published
09 Mar 2015

Med. Chem. Commun., 2015,6, 898-904

Author version available

Synthesis and evaluation of anticancer activity of novel andrographolide derivatives

P. Devendar, V. L. Nayak, D. K. Yadav, A. N. Kumar, J. K. Kumar, K. Satya Srinivas, B. Sridhar, F. Khan, K. P. Sastry and S. Ramakrishna, Med. Chem. Commun., 2015, 6, 898 DOI: 10.1039/C4MD00566J

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Spotlight

Advertisements